<DOC>
	<DOC>NCT01745094</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of concomitant use of mirabegron in patients with overactive bladder under treatment with solifenacin.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients</brief_title>
	<detailed_description>The duration of the study will be a total of 18 weeks including a 2-week screening period and 16 week treatment period. At week 8 visit, the dose of mirabegron can be increased based on agreement of the subject if mirabegron, in the opinion of the investigator or sub-investigator, is not fully effective.</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Female: postmenopausal OAB outpatient Male: OAB outpatient who has no wish to have children in the future Patient has been under treatment with solifenacin at a stable dose once daily for at least 4 weeks prior to the study Patient has a total OABSS score of ≥3 points and a Question 3 score ≥2 points Patient has a residual urine volume of ≥100 mL or a maximum flow rate &lt;5 mL/s, or patients with benign prostatic hyperplasia, or lower urinary tract obstruction Patient has serious heart disease (myocardial infarction, cardiac failure, uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver disease, kidney disease, immunological disease, lung disease, etc. or patient has malignant tumor (except for malignant tumor that has not been treated for at least 5 y before the start of the screening period with no risk of recurrence) Patient has received surgical therapy that may affect the urinary tract function within 24 wk before the start of the screening period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mirabegron</keyword>
	<keyword>solifenacin</keyword>
</DOC>